-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Daiichi Sankyo announced that the oral FLT3 inhibitor quizartinib, in combination with standard chemotherapy, met its primary endpoint in a Phase 3 clinical trial in the first-line treatment of patients with FLT3-ITD-mutated acute myeloid leukemia (AML).
AML is one of the most common leukemias in adults, accounting for about one-third of all cases
FLT3 is a transmembrane receptor tyrosine kinase protein, which is usually expressed by hematopoietic stem cells.
Quizartinib is an oral FLT3 inhibitor
▲ Molecular formula of Quizartinib (Image source: Ed (Edgar181), Public domain, via Wikimedia Commons)
The randomized, double-blind, placebo-controlled, multicenter Phase 3 trial enrolled 539 patients (18-75 years old) with AML with FLT3-ITD mutations
References:
[1] Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML.
(Original abridged)
